These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31369543)

  • 1. Cost-effectiveness of treating multidrug- and extensively drug-resistant tuberculosis: A systematic review.
    Vo NX; Thuy Nguyen TT; Phuong Thao NT; Thanh Ho HP; Vo TQ
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S131-S136. PubMed ID: 31369543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
    Dowdy DW; van't Hoog A; Shah M; Cobelens F
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.
    Lange C; Abubakar I; Alffenaar JW; Bothamley G; Caminero JA; Carvalho AC; Chang KC; Codecasa L; Correia A; Crudu V; Davies P; Dedicoat M; Drobniewski F; Duarte R; Ehlers C; Erkens C; Goletti D; Günther G; Ibraim E; Kampmann B; Kuksa L; de Lange W; van Leth F; van Lunzen J; Matteelli A; Menzies D; Monedero I; Richter E; Rüsch-Gerdes S; Sandgren A; Scardigli A; Skrahina A; Tortoli E; Volchenkov G; Wagner D; van der Werf MJ; Williams B; Yew WW; Zellweger JP; Cirillo DM;
    Eur Respir J; 2014 Jul; 44(1):23-63. PubMed ID: 24659544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing quality of life for multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Vo NX; Xuan Doan TB; Kha Vo DN; Tran TK; Vo TQ
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S137-S157. PubMed ID: 31369544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.
    Diel R; Vandeputte J; de Vries G; Stillo J; Wanlin M; Nienhaus A
    Eur Respir J; 2014 Feb; 43(2):554-65. PubMed ID: 23949960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 11. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.
    Mullerpattan JB; Udwadia ZZ; Banka RA; Ganatra SR; Udwadia ZF
    Indian J Tuberc; 2019 Jan; 66(1):87-91. PubMed ID: 30797290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-resistant Tuberculosis in the WHO European Region 2011-2015: Cost-effectiveness analysis.
    Jakab Z; Acosta CD; Kluge HH; Dara M
    Tuberculosis (Edinb); 2015 Jun; 95 Suppl 1():S212-6. PubMed ID: 25829287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.
    Günther G; Gomez GB; Lange C; Rupert S; van Leth F;
    Eur Respir J; 2015 Apr; 45(4):1081-8. PubMed ID: 25395035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional study about knowledge and attitudes toward multidrug-resistant and extensively drug-resistant tuberculosis in a high-burden drug-resistant country.
    Javed H; Tahir Z; Hashmi HJ; Jamil N
    Int J Mycobacteriol; 2016 Jun; 5(2):128-34. PubMed ID: 27242222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Marks SM; Mase SR; Morris SB
    Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
    Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
    JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.